
SOTIO Expands ADC Pipeline with Two Bispecific Candidates, SOT112 and SOT113
SOTIO Expands ADC Pipeline with Bispecific Candidates SOT112 and SOT113 SOTIO Biotech Advances Two Promising Bispecific Antibody-Drug Conjugate Programs SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, has announced an exciting development in its collaboration with Synaffix B.V.,…












